Aspira is now Offering Treatment for Patients with COVID: Bebtelovimab
- This is a monoclonal antibody used to treat patients with COVID.
- It is given as a slow IV injection over 30 seconds. Then we monitor patients for 1 hour to ensure there is no reaction.
- This medication is for anyone ≥12 years of age and weighing at least 40 kg.
- The dosage is bebtelovimab 175 mg administered as a single intravenous injection over at least 30 seconds.
- Administration of bebtelovimab is recommended to occur as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset.
- This medication is best for patients who are at high risk for progression to severe COVID-19, including hospitalization or death, and
- for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.
To get Bebtelovimab:
Contact us via text at 302-517-1385 and we can make arrangements for you to come into to get the treatment. You can also email us at firstname.lastname@example.org to arrange an injection.